FH and goblet cell carcinoma: Compared with the control group, higher cumulative incidence rates (ESCC: 13.0% vs. 18.7%, P <0.01; GCC: 7.8% vs. 10.0%, P <0.01) and mortality rates (ESCC: 11.5% vs. 16.0%, P <0.01; GCC: 6.5% vs. 8.5%, P <0.01) of ESCC and GCC were observed in the positive FH group, and no significant difference was observed for GNCC incidence (P = 0.12) and mortality (P = 0.30).